Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2017-03-22 Capital/Financing Update
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd. The core content of the filing is an announcement regarding the closing of a $2.8 million private placement of securities (ADSs and warrants). This falls under the category of company fundraising and financing activities. According to the provided definitions, documents detailing company fundraising, financing activities, or capital structure changes are classified as 'CAP'.
2017-03-22 English
Immediate Report
Capital/Financing Update Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange. The key content states: 'Attached hereto is a report on *closeing of a private offering of securities for proceeds of $2.8 million.*' This indicates the document itself is an announcement about a financing event (closing a private offering) rather than the detailed financial report (like 10-K or IR) or the presentation itself. Since it announces a financing activity, the most appropriate category is 'Capital/Financing Update' (CAP). Although it is an announcement, the core subject matter is financing, which is more specific than the general 'Report Publication Announcement' (RPA) or 'Regulatory Filing' (RNS), especially since the text explicitly mentions the nature of the event (private offering). Given the subject matter, CAP is the best fit.
2017-03-22 English
6-K
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the closing of a $2.8 million private placement financing, describing the issuance of American Depository Shares and warrants, terms of the offering, and related shareholder meeting plans. The content focuses on capital raising activities and financing details rather than financial results, management changes, or regulatory compliance. The document length is 7147 characters, which is sufficient for a substantive announcement. Given the focus on fundraising and capital structure changes, the appropriate classification is Capital/Financing Update (CAP).
2017-03-22 English
Immediate Report
Regulatory Filings Classification · 100% confidence The document explicitly states it is a "Form 6-K, Report of Foreign Private Issuer" filed with the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". Form 6-K is used by foreign private issuers to report material information not required to be reported under the home country's requirements or to furnish information to the SEC. The content details a private placement of American Depositary Shares (ADSs) and warrants, which is a significant corporate financing/capital event. While it relates to capital structure changes (CAP), the primary regulatory filing type for this specific SEC form is not directly listed among the primary options (10-K, IR, ER, etc.). Form 6-K is a general periodic/current report for foreign issuers. Given the provided definitions, and recognizing that Form 6-K is a mandatory SEC filing that doesn't fit neatly into the specific categories like 10-K (Annual Report) or ER (Earnings Release), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as the general category for miscellaneous SEC filings that don't match the specific definitions provided. However, since the document details a significant capital transaction (private placement of ADSs and warrants), it strongly relates to 'Capital/Financing Update' (CAP). Since Form 6-K is the vehicle used to report this material event, and it is not a 10-K, IR, or ER, RNS is the safest general classification for an SEC form not explicitly defined. But, because the core subject matter is a financing deal, CAP is highly relevant. Given the structure of the definitions, RNS is the best fit for an SEC filing type not covered by the specific report types (10-K, IR, ER, etc.). If the document were a press release announcing the financing, ER or RPA might apply, but this is the official SEC filing itself (Form 6-K). I will classify it as RNS as the catch-all for specific SEC forms not listed, although CAP describes the content.
2017-03-12 English
Immediate Report
Capital/Financing Update Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). The key sentence is: 'Attached hereto is a report on *private placement offering dated March 7, 2017 - related forms.*'. This indicates the document itself is an announcement about an attached filing related to a private placement offering. A private placement offering is a form of fundraising or capital structure change. Since the document is short (1831 chars) and explicitly states that the substantive report is 'attached' (following the 'MENU VS MEAL' rule), it should be classified as a Report Publication Announcement (RPA) or potentially Capital/Financing Update (CAP). Given the explicit mention of 'Attached hereto is a report on *private placement offering*', RPA is the most precise classification for the announcement itself, although CAP is the underlying subject matter. However, looking at the definitions, 'Capital/Financing Update (CAP)' covers 'Updates on company fundraising, financing activities, or capital structure changes.' A private placement is a financing activity. Since the document is an official regulatory filing announcing this specific financing event, CAP is a strong candidate. If the document were the actual private placement memorandum, it would be CAP. As it is the announcement of the attached forms related to the private placement, it fits well under CAP as an update on financing, or RPA as the announcement mechanism. Given the context of 'private placement offering' being a financing event, CAP is slightly more specific than the general RPA announcement code. I will select CAP as the primary type, as the content is fundamentally about capital raising.
2017-03-12 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports a private placement financing transaction involving the sale of American Depositary Shares and warrants, including details about the offering terms, closing conditions, and shareholder meeting plans to increase authorized shares. The document is not a full financial report but an update on a capital raising event. It includes legal disclaimers and references to attached agreements. The content fits the definition of a Capital/Financing Update (CAP) as it provides information on fundraising and capital structure changes. The document length (5834 characters) supports it being a substantive filing rather than a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2017-03-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.